NasdaqGS:EWTXPharmaceuticals
Why Edgewise Therapeutics (EWTX) Is Up 21.5% After Positive Trial, FDA Updates And Equity Grants
Edgewise Therapeutics recently reported positive outcomes from drug trials and FDA-related developments, while also granting inducement stock options for 266,000 shares to nine new non-executive employees under its 2024 Inducement Equity Incentive Plan.
These clinical updates, combined with a catalyst-rich pipeline and management’s decision to expand the team with equity-linked hires, highlight the company’s focus on executing its late- and mid-stage programs.
We’ll now examine how the...